BIOTIE THERAPIES CORP. Stock Exchange Release 28
January 2014 at 9.00 am
Biotie: Change in the number of votes
Biotie Therapies Corp. ("Biotie" or the "Company") has conveyed Biotie shares
held as treasury shares and that were issued on 2 January 2014 pursuant to the
Stock Option Plan 2011 and the Equity Incentive Plan 2011 as follows:
Shares Cumulative shares Remaining shares to
conveyed conveyed since 2 be conveyed
January 2014
323,750 323,750 2,997,910
Under the Stock Option Plan 2011, the owners of the stock options may subscribe
for a maximum total of 7,401,000 new shares in the Company or existing shares
held by the Company. A total of 232,500 shares have been subscribed for during
the period 2 January 2014 and 27 January 2014 and 232,500 of the treasury shares
will be used for these share subscriptions. The subscription price of EUR 0.01
per share has been fully paid by the employees and the EUR 2,325 funds received
will be credited to the Company's reserve for non-restricted equity.
The first vesting period of the Equity Incentive Plan 2011 ended on 5 January
2014, after which the Company's shares shall be delivered to employees on the
basis of the granted share units. It was resolved pursuant to the authorization
of the Annual General Meeting of the Shareholders held on 4 April 2013 to issue
91,250 existing treasury shares to the employees without consideration for the
purposes of remunerating the employees pursuant to the terms and conditions of
the Equity Incentive Plan 2011 and thus there is an especially weighty financial
reason to derogate from the pre-emptive right of the shareholders, as referred
to in Chapter 9 Section 4(1) of the Companies Act (624/2006, as amended).
The conveyed shares previously held as treasury shares have not carried any
voting rights. The conveyance does not affect the number of registered shares.
After the conveyances the changes are as follows:
Increase in number Total amount of Number of the Total number
of outstanding shares voting rights Company's shares held of registered
by the Group shares
323,750 446,537,698 9,494,700 456,032,398
Turku, 28 January 2014
Biotie Therapies Corp.
Timo Veromaa, President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
www.biotie.com
DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media
[HUG#1757460]